Replies to post #8530 on SmallCap Trading Techniques

[catmaniac]

I"m not following any of these stocks tony...
I only posted that list as a favor for Mickey a while back.
He wanted a list of the bio's that were to present at the
confrence that they had last fall.
I'm no longer trading microcaps at this time.
catman...ISYA

PS...at least I'm no longer buyin any NEW positions...and
just wishin that I'll be able to see a profit on any of
the one's that I'm now holding.
Best of luck to those who can make it in this market though.

[Bull Trader]

NKTR BUYOUT OF GNBT RUMORS SWIRLING... 6 minutes ago http://finance.yahoo.com/q?s=NKTR

They have a similair product and may be interested in acquiring GNBT now that orders are coming in. They have an interest in the Asian market - specifically India.


Sentiment : Strong Buy
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_G/threadview?m=tm&bn=7923&tid=432276&mid=432276&tof=2&frt=2

[I Like Bottom Fishing]

GNBT News Generex Study Proposes Increased Reporting of Clin...
Wednesday, May 7, 2008 8:01 AM


From:
"[e-mail]" <[e-mail]>
View contact details



Scottrade.com
This email is compliments of Scottrade.com
If you would like to modify or suspend this alert, please login to your Scottrade account and navigate to the "Alerts" page under the "My Account" tab.


News for 'GNBT' - (Generex Study Proposes Increased Reporting of Clinical Outcomes to Support Reimbursement of Non-Injectable Insulin Options Findings Presented At International Society for Pharmacoeconomics and Outcomes Research Meeting in Toronto)


WORCESTER, Mass., May 7, 2008 (PrimeNewswire via COMTEX) -- Generex
Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for
metabolic diseases through the inner lining of the mouth, announced today that
it has sponsored a poster presentation at this year's International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) meeting being held in Toronto,
Canada May 3-7, 2008. The project was carried out by Pivina Consulting Inc.
during 2007.

The title of the poster is "Non-injectable Insulin -- To Pay or Not to Pay." The
poster is co-authored by Charles Piwko, N. Mittman, S.J. Seung, Anita Kapoor and
George Markus. George Markus, M.Sc., is Generex's Vice President of Regulatory
Affairs and Anita Kapoor, Ph.D., is a Regulatory Affairs Associate at the
Company.

The objective of the abstract is to examine what may have contributed to minimal
governmental reimbursements of non-injectable insulin costs. The report explores
existing insulin treatments and future treatments and the rationales for
reimbursement.

Major findings were that clinical studies for non-injectable insulins did not
include adequate information and/or outcomes that are required by decision
makers for reimbursement recommendations; patient satisfaction according to the
HTA agencies was considered to be an important outcome, but was not well
reported in the clinical studies; there is a need to include utility data.

The report concludes that, since there is a lack of adequately evaluated
outcomes demonstrating the link between improved adherence and improved clinical
outcomes, there exists a definite need to re-examine the rationales for the lack
of reimbursement.

"We are pleased to have taken some necessary steps in the assessment of
reimbursement evaluations and listing criteria," said Rose C. Perri, the
Company's Chief Operating Officer. "This research will pave the way for the
conduct of an upcoming utility study of our proprietary oral insulin spray
product, Generex Oral-lyn(tm). These Health Economic initiatives will play a
role in supporting future reimbursement recommendations."

ISPOR promotes the science of pharmacoeconomics (health economics) and outcomes
research (the scientific discipline that evaluates the effect of health care
interventions on patient well-being including clinical outcomes, economic
outcomes, and patient-reported outcomes) and facilitates the translation of this
research into useful information for healthcare decision-makers to ensure that
society allocates scarce health care resources wisely, fairly and efficiently.

About Generex

Generex is engaged in the research, development, and commercialization of drug
delivery systems and technologies. Generex has developed a proprietary platform
technology for the delivery of drugs into the human body through the oral cavity
(with no deposit in the lungs). The Company's proprietary liquid formulations
allow drugs typically administered by injection to be absorbed into the body by
the lining of the inner mouth using the Company's proprietary RapidMist(tm)
device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)),
which is available for sale in Ecuador for the treatment of patients with Type-1
and Type-2 diabetes and which was approved for sale in India in October 2007, is
in various stages of clinical development around the world. For more
information, visit the Generex website at www.generex.com.

The Generex Biotechnology Corp. logo is available at
http://www.primenewswire.com/newsroom/prs/?pkgid=3831

Safe Harbor Statement: This release and oral statements made from time to time
by Generex representatives concerning the same subject matter may contain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements can be identified by
introductory words such as "expects," "plans," "intends," "believes," "will,"
"estimates," "forecasts," "projects" or words of similar meaning, and by the
fact that they do not relate strictly to historical or current facts.
Forward-looking statements frequently are used in discussing potential product
applications, potential collaborations, product development activities, clinical
studies, regulatory submissions and approvals, and similar operating matters.
Many factors may cause actual results to differ from forward-looking statements,
including inaccurate assumptions and a broad variety of risks and uncertainties,
some of which are known and others of which are not. Known risks and
uncertainties include those identified from time to time in the reports filed by
Generex with the Securities and Exchange Commission, which should be considered
together with any forward-looking statement. No forward-looking statement is a
guarantee of future results or events, and one should avoid placing undue
reliance on such statements. Generex undertakes no obligation to update publicly
any forward-looking statements, whether as a result of new information, future
events or otherwise. Generex cannot be sure when or if it will be permitted by
regulatory agencies to undertake additional clinical trials or to commence any
particular phase of clinical trials. Because of this, statements regarding the
expected timing of clinical trials cannot be regarded as actual predictions of
when Generex will obtain regulatory approval for any "phase" of clinical trials.
Generex claims the protection of the safe harbor for forward-looking statements
that is contained in the Private Securities Litigation Reform Act.

This news release was distributed by PrimeNewswire, www.primenewswire.com

SOURCE: Generex Biotechnology Corp.


By Staff

CONTACT: For Generex: American Capital Ventures, Inc. Howard Gostfrand 305-918-7000 CEOcast, Inc. Gary Nash 212-732-4300




(C) Copyright 2008 PrimeNewswire, Inc. All rights reserved.

-0-




INDUSTRY KEYWORD: Biotechnology

SUBJECT CODE: BIOTECHNOLOGY

HEALTH

MEDICAL

PHARMACEUTICALS

TRADE SHOW

Product Services Announcement

Trade Show

Calendar of Events

Health

Source: Comtex Wall Street News
Go to Previous message | Go to Next message | Back to Messages
ASCII (ASCII)Greek (ISO-8859-7)Greek (Windows-1253)Latin-10 (ISO-8859-16)Latin-3 (ISO-8859-3)Latin-6 (ISO-8859-10)Latin-7 (ISO-8859-13)Latin-8 (ISO-8859-14)Latin-9 (ISO-8859-15)W. European (850)W. European (CP858)W. European (HPROMAN8)W. European (MACROMAN8)W. European (Windows-1252)Armenia (ARMSCII-8)Baltic Rim (ISO-8859-4)Baltic Rim (WINDOWS-1257)Cyrillic (866)Cyrillic (ISO-8859-5)Cyrillic (KOI8-R)Cyrillic (KOI8-RU)Cyrillic (KOI8-T)Cyrillic (KOI8-U)Cyrillic (WINDOWS-1251)Latin-2 (852)Latin-2 (ISO-8859-2)Latin-2 (WINDOWS-1250)Turkish (ISO-8859-9)Turkish (WINDOWS-1254)Arabic (ISO-8859-6, ASMO-708)Arabic (WINDOWS-1256)Hebrew (856)Hebrew (862)Hebrew (WINDOWS-1255)Chinese Simplified (GB-2312-80)Chinese Simplified (GB18030)Chinese Simplified (HZ-GB-2312)Chinese Simplified (ISO-2022-CN)Chinese Simplified (WINDOWS-936)Chinese Trad.-Hong Kong (BIG5-HKSCS)Chinese Traditional (BIG5)Chinese Traditional (EUC-TW)Japanese (SHIFT_JIS)Japanese (EUC-JP)Japanese (ISO-2022-JP)Korean (ISO-2022-KR)Korean (EUC-KR)Thai (TIS-620-2533)Thai (WINDOWS-874)Vietnamese (TCVN-5712)Vietnamese (VISCII)Vietnamese (WINDOWS-1258)Unicode (UTF-7)Unicode (UTF-8)Unicode (UTF-16)Unicode (UTF-32)
| Full Headers
Search Mail

[I Like Bottom Fishing]

GNBT News Generex Biotechnology Presented Data At The Endocr...
Thursday, June 19, 2008 9:31 AM

From:
"[e-mail]" <[e-mail]>
View contact details

Scottrade.com
This email is compliments of Scottrade.com

If you would like to modify or suspend this alert, please login to your Scottrade account and navigate to the "Alerts" page under the "My Account" tab.


News for 'GNBT' - (Generex Biotechnology Presented Data At The Endocrine Society's Annual Meeting Study Demonstrates Value of Human Insulin Therapy)


WORCESTER, Mass., Jun 19, 2008 (PrimeNewswire via COMTEX) -- Generex
Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug
delivery for metabolic diseases through the inner lining of the mouth, made a
podium presentation of data from a company-sponsored study at The Endocrine
Society's 90th Annual Meeting (ENDO, www.endo-society.org) in San Francisco on
June 18, 2008.

Doctor Jaime Guevara-Aguirre of the Institute of Endocrinology IEMYR, Quito,
Ecuador, made a podium presentation of an abstract entitled, "Human Insulin
Therapy is Safe, Efficacious, and Less Costly Than Insulin Analogs in the
Treatment of Type-1 Diabetes." The abstract was co-authored by Doctor Jaime
Guevara-Aguirre and Doctor Marco Guevara-Aguirre, both of the Institute of
Endocrinology IEMYR; Professor Arlan L. Rosenbloom of the University of Florida;
and Dr. Gerald Bernstein, the company's Vice-President for Medical Affairs.

The one-year study compared the efficacy and safety of analog versus human
insulins. The study showed that human insulin administered as basal injection
and with meals as orally absorbed regular insulin (Generex Oral-lyn(tm), the
company's proprietary oral insulin spray product) attained lower pre-meal
glucose, HbA1c, and fructosamine concentrations when compared with a regimen
using basal and pre-prandial insulin analogs in Type-1 diabetes. The cost of
insulin analogs, basal and pre-prandial, is greater than that of recombinant
human insulin, but this greater expense has been considered justified by
therapeutic advantages. The study concluded that human insulin, when delivered
through the buccal mucosa, is not inferior to analogues in the long-term
treatment of Type-1 diabetes and could be used as a less costly alternative.

The company also made a poster presentation of an abstract entitled, "Serum
Fructosamine Measurement is Adequate for Monitoring Long-Term Metabolic Control
in Type-1 Diabetes." The abstract was co-authored by Doctors Jaime
Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra, all of the
Institute of Endocrinology IEMYR, Quito, Ecuador; Edward Vidgen of the
University of Toronto; Professor Arlan L. Rosenbloom of the University of
Florida; and Dr. Gerald Bernstein, the company's Vice-President for Medical
Affairs.

About The Endocrine Society

ENDO's mission is to advance excellence in endocrinology and promote its
essential role as an integrative force in scientific research and medical
practice. ENDO is an international body with thirteen thousand members from over
eighty-five countries. The diverse membership represents medicine, molecular and
cellular biology, biochemistry, physiology, genetics, immunology, education,
industry, and allied health. Society members represent the full range of
disciplines associated with endocrinologists: clinicians, researchers,
educators, fellows and students, industry professionals, and health
professionals who are involved in the field of endocrinology. These
professionals are dedicated to the research and treatment of the full range of
endocrine disorders: diabetes, reproduction, infertility, osteoporosis, thyroid
disease, obesity/lipids, growth hormone, pituitary tumors, and adrenal
insufficiency. ENDO works to foster a greater understanding of endocrinology
amongst the general public and practitioners of complementary medical
disciplines and to promote the interests of all endocrinologists at the national
scientific research and health policy levels of government.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug
delivery systems and technologies. Generex has developed a proprietary platform
technology for the delivery of drugs into the human body through the oral cavity
(with no deposit in the lungs). The Company's proprietary liquid formulations
allow drugs typically administered by injection to be absorbed into the body by
the lining of the inner mouth using the Company's proprietary RapidMist(tm)
device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)),
which is available for sale in Ecuador for the treatment of patients with Type-1
and Type-2 diabetes and which was approved for sale in India in October 2007, is
in Phase 3 clinical trials at several sites around the world. For more
information, visit the Generex website at www.generex.com.

The Generex Biotechnology Corp. logo is available at
http://www.primenewswire.com/newsroom/prs/?pkgid=3831

Safe Harbor Statement

This release and oral statements made from time to time by Generex
representatives concerning the same subject matter may contain "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements can be identified by introductory words such as
"expects," "plans," "intends," "believes," "will," "estimates," "forecasts,"
"projects," or words of similar meaning, and by the fact that they do not relate
strictly to historical or current facts. Forward-looking statements frequently
are used in discussing potential product applications, potential collaborations,
product development activities, clinical studies, regulatory submissions and
approvals, and similar operating matters. Many factors may cause actual results
to differ from forward-looking statements, including inaccurate assumptions and
a broad variety of risks and uncertainties, some of which are known and others
of which are not. Known risks and uncertainties include those identified from
time to time in the reports filed by Generex with the Securities and Exchange
Commission, which should be considered together with any forward-looking
statement. No forward-looking statement is a guarantee of future results or
events, and one should avoid placing undue reliance on such statements. Generex
undertakes no obligation to update publicly any forward-looking statements,
whether as a result of new information, future events or otherwise. Generex
cannot be sure when or if it will be permitted by regulatory agencies to
undertake additional clinical trials or to commence any particular phase of
clinical trials. Because of this, statements regarding the expected timing of
clinical trials cannot be regarded as actual predictions of when Generex will
obtain regulatory approval for any "phase" of clinical trials. Generex claims
the protection of the safe harbor for forward-looking statements that is
contained in the Private Securities Litigation Reform Act.

This news release was distributed by PrimeNewswire, www.primenewswire.com

SOURCE: Generex Biotechnology Corp.


By Staff

CONTACT: CEOcast, Inc. For Generex: Gary Nash 212-732-4300 American Capital Ventures, Inc. Howard Gostfrand 305-918-7000




(C) Copyright 2008 PrimeNewswire, Inc. All rights reserved.

-0-




INDUSTRY KEYWORD: Biotechnology

SUBJECT CODE: HEALTH

MEDICAL

Calendar of Events

Health

Source: Comtex Wall Street News
Go to Previous message | Go to Next message | Back to Messages
ASCII (ASCII)Greek (ISO-8859-7)Greek (Windows-1253)Latin-10 (ISO-8859-16)Latin-3 (ISO-8859-3)Latin-6 (ISO-8859-10)Latin-7 (ISO-8859-13)Latin-8 (ISO-8859-14)Latin-9 (ISO-8859-15)W. European (850)W. European (CP858)W. European (HPROMAN8)W. European (MACROMAN8)W. European (Windows-1252)Armenia (ARMSCII-8)Baltic Rim (ISO-8859-4)Baltic Rim (WINDOWS-1257)Cyrillic (866)Cyrillic (ISO-8859-5)Cyrillic (KOI8-R)Cyrillic (KOI8-RU)Cyrillic (KOI8-T)Cyrillic (KOI8-U)Cyrillic (WINDOWS-1251)Latin-2 (852)Latin-2 (ISO-8859-2)Latin-2 (WINDOWS-1250)Turkish (ISO-8859-9)Turkish (WINDOWS-1254)Arabic (ISO-8859-6, ASMO-708)Arabic (WINDOWS-1256)Hebrew (856)Hebrew (862)Hebrew (WINDOWS-1255)Chinese Simplified (GB-2312-80)Chinese Simplified (GB18030)Chinese Simplified (HZ-GB-2312)Chinese Simplified (ISO-2022-CN)Chinese Simplified (WINDOWS-936)Chinese Trad.-Hong Kong (BIG5-HKSCS)Chinese Traditional (BIG5)Chinese Traditional (EUC-TW)Japanese (SHIFT_JIS)Japanese (EUC-JP)Japanese (ISO-2022-JP)Korean (ISO-2022-KR)Korean (EUC-KR)Thai (TIS-620-2533)Thai (WINDOWS-874)Vietnamese (TCVN-5712)Vietnamese (VISCII)Vietnamese (WINDOWS-1258)Unicode (UTF-7)Unicode (UTF-8)Unicode (UTF-16)Unicode (UTF-32)
| Full Headers
Search Mail